抄録
The predominant histological types of esophageal cancer are adenocarcinoma and squamous cell carcinoma. Since these two histological types present as different diseases in terms of their epidemiology, pathologenesis, and tumor biology, separate therapeutic approaches should be developed against each type. While surgical resection remains the dominant therapeutic intervention for patients with operable esophageal squamous cell carcinoma (ESCC), their high rates of tumor recurrence have prompted investigation of multimodality therapies that combine surgery with chemotherapy, radiotherapy, and chemoradiotherapy. In Japan, preoperative chemotherapy with cisplatin (CDDP) plus 5-fluorouracil (5-FU) followed by radical esophagectomy has been accepted as the standard therapeutic approach for resactable clinical Stage II/III ESCC. Similarly, the CDDP and 5-FU regimen has been accepted as the first-line treatment for metastatic and unresectable ESCCs in Japan. Thus, in Japan chemotherapy is an indispensable component of therapy for both resectable and unresectable ESCCs. This review discusses the current knowledge, rationale, and available data regarding chemotherapy for resectable and unresectable ESCCs.
| 元の言語 | 英語 |
|---|---|
| 記事番号 | 12521 |
| ジャーナル | Diseases of the Esophagus |
| 巻 | 30 |
| 発行部数 | 2 |
| DOI | |
| 出版物ステータス | 出版済み - 2 1 2017 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Gastroenterology
これを引用
Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma. / Baba, Y.; Saeki, Hiroshi; Nakashima, Yuichiro; Oki, Eiji; Shigaki, H.; Yoshida, N.; Watanabe, M.; Maehara, Yoshihiko; Baba, Hideo.
：: Diseases of the Esophagus, 巻 30, 番号 2, 12521, 01.02.2017.研究成果: ジャーナルへの寄稿 › 評論記事
}
TY - JOUR
T1 - Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma
AU - Baba, Y.
AU - Saeki, Hiroshi
AU - Nakashima, Yuichiro
AU - Oki, Eiji
AU - Shigaki, H.
AU - Yoshida, N.
AU - Watanabe, M.
AU - Maehara, Yoshihiko
AU - Baba, Hideo
PY - 2017/2/1
Y1 - 2017/2/1
N2 - The predominant histological types of esophageal cancer are adenocarcinoma and squamous cell carcinoma. Since these two histological types present as different diseases in terms of their epidemiology, pathologenesis, and tumor biology, separate therapeutic approaches should be developed against each type. While surgical resection remains the dominant therapeutic intervention for patients with operable esophageal squamous cell carcinoma (ESCC), their high rates of tumor recurrence have prompted investigation of multimodality therapies that combine surgery with chemotherapy, radiotherapy, and chemoradiotherapy. In Japan, preoperative chemotherapy with cisplatin (CDDP) plus 5-fluorouracil (5-FU) followed by radical esophagectomy has been accepted as the standard therapeutic approach for resactable clinical Stage II/III ESCC. Similarly, the CDDP and 5-FU regimen has been accepted as the first-line treatment for metastatic and unresectable ESCCs in Japan. Thus, in Japan chemotherapy is an indispensable component of therapy for both resectable and unresectable ESCCs. This review discusses the current knowledge, rationale, and available data regarding chemotherapy for resectable and unresectable ESCCs.
AB - The predominant histological types of esophageal cancer are adenocarcinoma and squamous cell carcinoma. Since these two histological types present as different diseases in terms of their epidemiology, pathologenesis, and tumor biology, separate therapeutic approaches should be developed against each type. While surgical resection remains the dominant therapeutic intervention for patients with operable esophageal squamous cell carcinoma (ESCC), their high rates of tumor recurrence have prompted investigation of multimodality therapies that combine surgery with chemotherapy, radiotherapy, and chemoradiotherapy. In Japan, preoperative chemotherapy with cisplatin (CDDP) plus 5-fluorouracil (5-FU) followed by radical esophagectomy has been accepted as the standard therapeutic approach for resactable clinical Stage II/III ESCC. Similarly, the CDDP and 5-FU regimen has been accepted as the first-line treatment for metastatic and unresectable ESCCs in Japan. Thus, in Japan chemotherapy is an indispensable component of therapy for both resectable and unresectable ESCCs. This review discusses the current knowledge, rationale, and available data regarding chemotherapy for resectable and unresectable ESCCs.
UR - http://www.scopus.com/inward/record.url?scp=85005877115&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85005877115&partnerID=8YFLogxK
U2 - 10.1111/dote.12521
DO - 10.1111/dote.12521
M3 - Review article
C2 - 27868285
AN - SCOPUS:85005877115
VL - 30
JO - Diseases of the Esophagus
JF - Diseases of the Esophagus
SN - 1120-8694
IS - 2
M1 - 12521
ER -